We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
-5.38%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$530M
AUM Growth
+$88.9M
Cap. Flow
+$121M
Cap. Flow %
22.77%
Top 10 Hldgs %
58.16%
Holding
331
New
70
Increased
91
Reduced
51
Closed
65

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$32.3M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$24M
3
BBIO icon
BridgeBio Pharma
BBIO
+$19.5M
4
ROIV icon
Roivant Sciences
ROIV
+$14.9M
5
RPRX icon
Royalty Pharma
RPRX
+$12.8M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.1M
2
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$13.3M
3
EDR
Endeavor Group Holdings, Inc.
EDR
+$3.85M
4
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$3.78M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$3.42M

Sector Composition

Rank Sector Weight
1 Healthcare 80.42%
2 Financials 1.75%
3 Industrials 0.22%
4 Utilities 0.17%
5 Technology 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LNTH icon
301
Lantheus
LNTH
$6.6B
– –
-1,000
Closed -$62.2K
LQDA icon
302
Liquidia Corp
LQDA
$7.95B
– –
-2,000
Closed -$29.5K
MCK icon
303
McKesson
MCK
$102B
– –
-250
Closed -$134K
MO icon
304
Altria Group
MO
$113B
– –
-2,000
Closed -$87.2K
MRVI icon
305
Maravai LifeSciences
MRVI
$922M
– –
-1,000
Closed -$8.67K
MX icon
306
Magnachip Semiconductor
MX
$141M
– –
-7,000
Closed -$39.1K
RAPT
307
PUT
DELISTED
RAPT Therapeutics
RAPT
– –
-938
Closed -$67.3K
REGN icon
308
Regeneron Pharmaceuticals
REGN
$79.5B
– –
-2,300
Closed -$2.21M
SDGR icon
309
Schrodinger
SDGR
$1.33B
– –
-63,586
Closed -$1.72M
SRPT icon
310
CALL
Sarepta Therapeutics
SRPT
$1.77B
– –
-1,200
Closed -$155K
SRZN icon
311
Surrozen
SRZN
$251M
– –
-450
Closed -$7.07K
STOK icon
312
Stoke Therapeutics
STOK
$2.06B
– –
-2,900
Closed -$39.1K
TARA icon
313
Protara Therapeutics
TARA
$230M
– –
-2,000
Closed -$8.02K
TVTX icon
314
Travere Therapeutics
TVTX
$5.89B
– –
-100
Closed -$771
VERU icon
315
Veru
VERU
$37.1M
– –
-33,607
Closed -$235K
VTGN icon
316
VistaGen Therapeutics
VTGN
$12.6M
– –
-89,938
Closed -$475K
ZYME icon
317
Zymeworks
ZYME
$1.7B
– –
-1,900
Closed -$20K
DJT icon
318
CALL
Trump Media & Technology Group
DJT
$2.74B
– –
-4,500
Closed -$279K
SPLP
319
DELISTED
STEEL PARTNERS HOLDINGS L.P.
SPLP
– –
-341
Closed -$13.5K
GLST
320
DELISTED
Global Star Acquisition, Inc. Class A Common Stock
GLST
– –
-80,000
Closed -$857K
TLIS
321
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
– –
-300
Closed -$2.63K
MORF
322
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-19,701
Closed -$693K
ASLN
323
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
– –
-7,424
Closed -$36.5K
FLFVR
324
DELISTED
Feutune Light Acquisition Corporation Right
FLFVR
– –
-15,000
Closed -$1.28K
FLFVW
325
DELISTED
Feutune Light Acquisition Corporation Warrant
FLFVW
– –
-15,000
Closed -$510
10 11 12
13
14

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return

ADAR1 Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, ADAR1 Capital Management held 331 positions worth $530M, up 20% from $441M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

ADAR1 Capital Management deployed $121M of net new capital in Q2 2024, opening 70 new positions and adding to 91 existing holdings. Its largest new stake was Perceptive Capital Solutions: 750,000 shares worth $7.54M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 69% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $28.1M trimmed.

  • ADAR1 Capital Management's largest Q2 2024 buy was Perceptive Capital Solutions: 750,000 shares worth $7.54M.
  • ADAR1 Capital Management added most to Cytokinetics in Q2 2024, an estimated $32.3M increase.
  • ADAR1 Capital Management's biggest Q2 2024 reduction was Alnylam Pharmaceuticals, cutting an estimated $28.1M.
  • ADAR1 Capital Management fully exited Merrimack Pharmaceuticals, Inc. in Q2 2024, selling an estimated $13.3M.
  • ADAR1 Capital Management's ten largest holdings make up 58% of its $530M portfolio in Q2 2024.
  • ADAR1 Capital Management opened 70 new positions and closed 65 in Q2 2024.
  • ADAR1 Capital Management's portfolio value rose 20% quarter-over-quarter to $530M.

Based on ADAR1 Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.